Rubius Therapeutics, Inc. (RUBY): $21.75

0.26 (+1.21%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add RUBY to Watchlist
Sign Up

Industry: Biotech


Ranked

of 499

in industry

Rubius Therapeutics Inc (RUBY) Price Targets From Analysts

The tables below show price targets and recommendations from analysts covering Rubius Therapeutics Inc.

Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
5 $40 $20 $30.4 $22.8 33.33%

The Trend in the Analyst Price Target


RUBY's average price target has moved up $16.5 over the prior 147 days.

RUBY reports an average of 25.79% for its upside potential over the past 14 months.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-07-24 5 40 20 30.40 21.77 39.64%
2021-07-17 5 40 20 30.40 22.49 35.17%
2021-06-28 5 40 20 30.40 24.19 25.67%
2021-06-26 5 40 20 30.40 24.73 22.93%
2021-06-11 5 40 20 30.40 27.60 10.14%
2021-05-11 5 40 20 30.20 25.23 19.7%
2021-05-08 5 40 20 30.20 26.15 15.49%
2021-04-25 5 40 20 30.20 24.66 22.47%
2021-04-12 5 40 10 27.40 22.26 23.09%
2021-04-10 5 40 10 27.40 23.88 14.74%
2021-04-03 5 40 10 27.40 25.00 9.6%
2021-03-08 5 28 4 13.90 12.07 15.16%
2021-03-06 5 28 4 13.90 12.56 10.67%
2021-02-27 5 28 4 13.90 10.38 33.91%
2021-02-20 6 28 5 11.50 12.64 -9.02%
2021-02-13 6 28 5 11.50 12.96 -11.27%
2021-02-06 6 28 5 11.50 13.81 -16.73%
2021-01-13 7 28 3 9.57 8.85 8.14%
2021-01-09 6 28 5 10.67 9.53 11.96%
2021-01-02 6 28 5 10.67 7.59 40.58%
2020-12-26 6 28 5 10.67 8.04 32.71%
2020-12-19 6 28 5 10.67 7.49 42.46%
2020-11-23 6 28 5 10.67 5.92 80.24%
2020-11-11 7 28 3 9.57 4.75 101.47%
2020-10-13 7 28 3 9.43 5.69 65.73%
2020-07-25 6 28 3 10.00 NA NA%
2020-05-27 6 28 3 10.00 NA NA%

RUBY Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1.58 2 1 3 0 0 6

Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.

  • The variance in analysts' estimates of RUBY is lower than 14.03% of all US stocks.
  • The upside potential (average analyst target price relative to current price) of RUBY is greater than 20.97% of Pharmaceutical Products stocks.
  • Rubius Therapeutics Inc's number of analysts covering the stock is greater than 30.15% of stocks in the mid market cap category.
  • Rubius Therapeutics Inc's average analyst price target is higher than 62.91% of Pharmaceutical Products stocks.

Stocks similar to Rubius Therapeutics Inc in the Pharmaceutical Products industry regarding analyst recommendations and price targets are OVID, PBH and RXRX.

Make investment decisions regarding RUBY using the data that counts. Try POWR Ratings for free.


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.659 seconds.